Helping more people survive skin cancer
 
Medically proven Artificial Intelligence

Our Vision

We want to help build a future where no one dies from skin cancer. 

Skin Analytics is a healthcare company that uses a custom developed artificial intelligence algorithm, DERM AI, to create innovative skin cancer pathways. AI for skin cancer helps to deliver better patient outcomes that are sustainable for health systems globally.

Skin Analytics delivers cutting edge AI for skin cancer detection.

Easier access. Faster diagnosis. Fewer referrals.

Why Skin Analytics

Artificial intelligence has the power to change healthcare forever. 

Skin Analytics has custom developed and medically tested DERM AI to ensure that it is an accurate tool that will help find skin cancer earlier. Using DERM AI means that people needing medical help can get it sooner while also providing peace of mind to those who don’t.

We don’t just say that. We invest time and resources to conduct ground breaking research. This helps to ensure that we deliver a healthcare solution with accuracy that is equivalent to a specialist.  Our research focused approach helps us work with clinicians to make a meaningful difference.

DERM AI checking a skin lesion for skin cancer

How Skin Analytics Helps

Skin Cancer Facts

Watch our CEO Neil Daly explain how using our technology can help save lives and improve healthcare pathways.

  • Non melanoma skin cancer is the most common cancer in the UK.
  • Melanoma is the 5th most common cancer in the UK.
  • Melanoma is one of the most common types of cancer to affect 15-34 year old people
  • In England 470,000 cancer specialist appointments are conducted to find 8,500 melanoma and 30,000 SCC’s

Our Awards

News and Information @ Skin Analytics

Skin Analytics achieves Class IIa UKCA Mark for DERM. The UK’s first and only Class IIa certified AI dermatology device

Now a Class IIa medical device, DERM, uses machine learning algorithms to recognise the most common malignant, pre-malignant and benign skin lesions, including melanoma – the fifth most common cancer in the UK. Using a decade’s worth of research and development on skin lesions, it is designed to accelerate patient diagnosis and relieve pressure on the healthcare system. 

read more

The Story So Far…

10 years. It barely seems credible to me that Skin Analytics is now a decade old.  The last two years, in particular, have been such a blur that perhaps it’s a good time to take stock and think back on what we’ve learnt since beginning the company. No 6 St Chad’s...

read more

Partner with us

 

  • Our services are only available through our clinical partners in the UK. If you’re worried about your skin and haven’t been referred to us please speak to a doctor without delay.

 

Patient Safety and Quality Policy

Skin Analytics aims to provide best in class solutions for patients. We work to meet our customers and partners expectations by delivering on our brand vision with innovative and customer focused products and services.

We empower our teams to maintain a culture of innovation and continuous improvement, underpinned by an effective and efficient Quality Management System that complies with statutory and regulatory requirements.

We put safety and outcomes at the heart of what we do, to provide high quality products and services which are reliable, safe and compliant which is why we are so proud to have achieved ISO 13485:2016 compliance. MD 711728. 

Clinical Advisory Committee

Professor Scott Kitchnener

Professor Scott Kitchnener

Committee Chair. Primary Care Medical Service Director

Scott is a qualified specialist in medical leadership and management (FRACMA), a graduate of the AICD, a specialist public health physician (FAFPHM), while remaining a clinician with specialist standing as a general practitioner in rural practice. He has experience in health and education corporate governance and leadership in the private sector, public sector, higher education sector, international and Australian biotech sectors and in the military. His on-going research and experience have been in addressing health issues of developing nations, rural health and workforce, and particularly preventive approaches to public health challenges. 

Dr Niall Wilson

Dr Niall Wilson

Consultant Dermatologist

Niall qualified in Medicine from the University of Liverpool in 1991. He has been an NHS Consultant Dermatologist since 2000. He has special interests in skin cancer, hyperhidrosis and skin disorders in immunosuppressed patients. He has also been involved with postgraduate education for many years and is currently vice chair of the Specialist Advisory Committee for Dermatology, which oversees Dermatology training in the UK.

Dr Lucy Thomas

Dr Lucy Thomas

Consultant Dermatologist

Lucy is a Consultant Dermatologist at the Phoenix Hospital Group in London.

Professor Chris Hyde

Professor Chris Hyde

Health Economics

Chris is a professor of Public Health and Clinical Epidemiology at Exeter University. He is a School lead for research on test evaluation including systematic reviews, economic models and primary research. He leads the Exeter Test Group and is the diagnostics theme lead for PenCLAHRC. He is part of the Peninsula Technology Assessment Group (PenTAG). He directed the team delivering health technology assessments for national policy-making bodies, particularly NICE, from 2009 until 2015 and continues to support it by being the lead on HTAs of tests and through membership of its steering group. He is a long standing member of NICE’s Diagnositc Advisory Committee and recently joined the National Screening Committee.

Justin M Ko, MD, MBA

Justin M Ko, MD, MBA

CLINICAL ASSOCIATE PROFESSOR, DERMATOLOGY STANFORD UNIVERSITY

Dr. Ko joined Stanford Medicine in 2012 and serves as Director and Chief of Medical Dermatology for Stanford Health Care (SHC) while also spearheading the dermatology department’s efforts around network development, digital health, quality/safety/performance improvement, and value-based care. He is active in a number of leadership roles within the organization including co-chairing the Clinic Advisory Council, a forum of medical and executive leaders of Stanford Health Care’s Ambulatory clinics, and as a Service Medical Director.

His passion for melanoma, early cancer detection, and improving care delivery drives his efforts and research around leveraging advances in machine learning and artifical intelligence to increase the breadth of populations that can be reached. He chairs the American Academy of Dermatology’s Task Force Committee on Augmented Intelligence.